{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T10:44:58Z","timestamp":1784198698828,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-025-03438-x","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T15:54:02Z","timestamp":1763740442000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effects of canagliflozin combined with metformin therapy on insulin sensitivity in patients with type 2 diabetes mellitus"],"prefix":"10.1186","volume":"30","author":[{"given":"Yimin","family":"Shu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"3438_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2019.107843","volume":"157","author":"P Saeedi","year":"2019","unstructured":"Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843. https:\/\/doi.org\/10.1016\/j.diabres.2019.107843.","journal-title":"Diabetes Res Clin Pract"},{"key":"3438_CR2","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.metabol.2018.02.002","volume":"85","author":"WT Garvey","year":"2018","unstructured":"Garvey WT, Van Gaal L, Leiter LA, Vijapurkar U, List J, Cuddihy R, et al. Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes. Metabolism. 2018;85:32\u20137. https:\/\/doi.org\/10.1016\/j.metabol.2018.02.002.","journal-title":"Metabolism"},{"issue":"9","key":"3438_CR3","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1007\/s00125-017-4336-x","volume":"60","author":"E Sanchez-Rangel","year":"2017","unstructured":"Sanchez-Rangel E, Inzucchi SE. Metformin: clinical use in type 2 diabetes. Diabetologia. 2017;60(9):1586\u201393. https:\/\/doi.org\/10.1007\/s00125-017-4336-x.","journal-title":"Diabetologia"},{"issue":"7","key":"3438_CR4","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1611925.","journal-title":"N Engl J Med"},{"issue":"2","key":"3438_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta21020","volume":"21","author":"R Johnston","year":"2017","unstructured":"Johnston R, Uthman O, Cummins E, Clar C, Royle P, Colquitt J, et al. Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation. Health Technol Assess. 2017;21(2):1\u2013218. https:\/\/doi.org\/10.3310\/hta21020.","journal-title":"Health Technol Assess"},{"key":"3438_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.12494","author":"H Kaneto","year":"2017","unstructured":"Kaneto H, Obata A, Kimura T, Shimoda M, Okauchi S, Shimo N, et al. Beneficial effects of sodium-glucose cotransporter 2 inhibitors for preservation of pancreatic \u03b2-cell function and reduction of insulin resistance. J Diabetes. 2017. https:\/\/doi.org\/10.1111\/1753-0407.12494.","journal-title":"J Diabetes"},{"key":"3438_CR7","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa494","author":"AM Ali","year":"2020","unstructured":"Ali AM, Mari A, Martinez R, Al-Jobori H, Adams J, Triplitt C, et al. Improved beta cell glucose sensitivity plays predominant role in the decrease in HbA1c with Cana and Lira in T2DM. J Clin Endocrinol Metab. 2020. https:\/\/doi.org\/10.1210\/clinem\/dgaa494.","journal-title":"J Clin Endocrinol Metab"},{"key":"3438_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-022-00949-0","volume":"22","author":"Z Hao","year":"2022","unstructured":"Hao Z, Sun Y, Li G, Shen Y, Wen Y, Liu Y. Effects of canagliflozin and metformin on insulin resistance and visceral adipose tissue in people with newly-diagnosed type 2 diabetes. BMC Endocr Disord. 2022;22:37. https:\/\/doi.org\/10.1186\/s12902-022-00949-0.","journal-title":"BMC Endocr Disord"},{"issue":"7","key":"3438_CR9","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41574-019-0316-1","volume":"16","author":"MD Campbell","year":"2020","unstructured":"Campbell MD, Sathish T, Zimmet PZ, Thankappan KR, Oldenburg B, Owens DR, et al. Benefit of lifestyle-based T2DM prevention is influenced by prediabetes phenotype. Nat Rev Endocrinol. 2020;16(7):395\u2013400. https:\/\/doi.org\/10.1038\/s41574-019-0316-1.","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"3438_CR10","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/S2213-8587(16)00052-8","volume":"4","author":"JH Wu","year":"2016","unstructured":"Wu JH, Foote C, Blomster J, Toyama T, Perkovic V, Sundstr\u00f6m J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2016;4(5):411\u20139. https:\/\/doi.org\/10.1016\/S2213-8587(16)00052-8.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"21","key":"3438_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/nu15214671","volume":"15","author":"W Yang","year":"2023","unstructured":"Yang W, Jiang W, Guo S. Regulation of macronutrients in insulin resistance and glucose homeostasis during type 2 diabetes mellitus. Nutrients. 2023;15(21):4671. https:\/\/doi.org\/10.3390\/nu15214671.","journal-title":"Nutrients"},{"key":"3438_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2021.154770","volume":"119","author":"E Muzurovi\u0107","year":"2021","unstructured":"Muzurovi\u0107 E, Mikhailidis DP, Mantzoros C. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk. Metabolism. 2021;119:154770. https:\/\/doi.org\/10.1016\/j.metabol.2021.154770.","journal-title":"Metabolism"},{"issue":"7121","key":"3438_CR13","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nature05487","volume":"444","author":"LF Van Gaal","year":"2006","unstructured":"Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature. 2006;444(7121):875\u201380. https:\/\/doi.org\/10.1038\/nature05487.","journal-title":"Nature"},{"issue":"12","key":"3438_CR14","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2147\/DMSO.S184437.PMID:30787627;PMCID:PMC6363491","volume":"1","author":"H Jakher","year":"2019","unstructured":"Jakher H, Chang TI, Tan M, Mahaffey KW. Canagliflozin review - safety and efficacy profile in patients with T2DM. Diabetes Metab Syndr Obes. 2019;1(12):209\u201315. https:\/\/doi.org\/10.2147\/DMSO.S184437.PMID:30787627;PMCID:PMC6363491.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"4","key":"3438_CR15","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/phar.1903","volume":"37","author":"JM Trujillo","year":"2017","unstructured":"Trujillo JM, Nuffer WA. Impact of sodium-glucose cotransporter 2 inhibitors on nonglycemic outcomes in patients with type 2 diabetes. Pharmacotherapy. 2017;37(4):481\u201391. https:\/\/doi.org\/10.1002\/phar.1903.","journal-title":"Pharmacotherapy"},{"issue":"3","key":"3438_CR16","doi-asserted-by":"publisher","first-page":"E258","DOI":"10.1152\/ajpendo.00267.2023","volume":"326","author":"LA Jahn","year":"2024","unstructured":"Jahn LA, Hartline LM, Nguyen T, Aylor K, Horton WB, Liu Z, et al. Empagliflozin improves vascular insulin sensitivity and muscle perfusion in persons with type 2 diabetes. Am J Physiol Endocrinol Metab. 2024;326(3):E258\u201367. https:\/\/doi.org\/10.1152\/ajpendo.00267.2023.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"3438_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.molmet.2018.10.009","volume":"19","author":"T Suga","year":"2019","unstructured":"Suga T, Kikuchi O, Kobayashi M, Matsui S, Yokota-Hashimoto H, Wada E, et al. SGLT1 in pancreatic \u03b1 cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels. Mol Metab. 2019;19:1\u201312. https:\/\/doi.org\/10.1016\/j.molmet.2018.10.009.","journal-title":"Mol Metab"},{"key":"3438_CR18","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00110.2012","author":"S Lee","year":"2012","unstructured":"Lee S, Zhang H, Chen J, Dellsperger KC, Hill MA, Zhang C. Adiponectin abates diabetes-induced endothelial dysfunction by suppressing oxidative stress, adhesion molecules, and inflammation in type 2 diabetic mice. Am J Physiol Heart Circ Physiol. 2012. https:\/\/doi.org\/10.1152\/ajpheart.00110.2012.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"3438_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.6065\/apem.2040188.094","volume":"26","author":"J Kim","year":"2021","unstructured":"Kim J, Lee J. Role of obesity-induced inflammation in the development of insulin resistance and type 2 diabetes: history of the research and remaining questions. Ann Pediatr Endocrinol Metab. 2021;26(1):1\u201313. https:\/\/doi.org\/10.6065\/apem.2040188.094.","journal-title":"Ann Pediatr Endocrinol Metab"},{"issue":"14","key":"3438_CR20","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","volume":"382","author":"WT Cefalu","year":"2013","unstructured":"Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382(14):941\u201350. https:\/\/doi.org\/10.1016\/S0140-6736(13)60683-2.","journal-title":"Lancet"},{"issue":"3","key":"3438_CR21","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2337\/dc13-2762","volume":"38","author":"LA Leiter","year":"2015","unstructured":"Leiter LA, Yoon KH, Arias P, Langslet G, Xie J, Balis DA, et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care. 2015;38(3):355\u201364. https:\/\/doi.org\/10.2337\/dc13-2762.","journal-title":"Diabetes Care"},{"issue":"9","key":"3438_CR22","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S2213-8587(14)70120-2","volume":"2","author":"M Ridderstr\u00e5le","year":"2014","unstructured":"Ridderstr\u00e5le M, Andersen KR, Zeller C, Kim G, Woerle HJ, Broedl UC, et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2(9):691\u2013700. https:\/\/doi.org\/10.1016\/S2213-8587(14)70120-2.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"34","key":"3438_CR23","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1093\/eurheartj\/ehv239","volume":"36","author":"E Ferrannini","year":"2015","unstructured":"Ferrannini E, DeFronzo RA. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur Heart J. 2015;36(34):2288\u201396. https:\/\/doi.org\/10.1093\/eurheartj\/ehv239.","journal-title":"Eur Heart J"},{"issue":"2","key":"3438_CR24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1560\/jafes.037.02.04","volume":"37","author":"P Ferwani","year":"2022","unstructured":"Ferwani P, Maldar A, Shah N, Chauhan P, Chadha M. Prevalence of bacterial urinary tract infection among patients with type 2 diabetes mellitus on sodium-glucose cotransporter-2 inhibitors: a prospective real-world setting study. J ASEAN Fed Endocr Soc. 2022;37(2):5\u20138. https:\/\/doi.org\/10.1560\/jafes.037.02.04.","journal-title":"J ASEAN Fed Endocr Soc"},{"issue":"1","key":"3438_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-017-0126-9","volume":"18","author":"PK Bundhun","year":"2017","unstructured":"Bundhun PK, Janoo G, Huang F. Adverse drug events observed in patients with type 2 diabetes mellitus treated with 100 mg versus 300 mg canagliflozin: a systematic review and meta-analysis of published randomized controlled trials. BMC Pharmacol Toxicol. 2017;18(1):19. https:\/\/doi.org\/10.1186\/s40360-017-0126-9.","journal-title":"BMC Pharmacol Toxicol"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03438-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-03438-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03438-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T15:54:03Z","timestamp":1763740443000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-025-03438-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3438"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-03438-x","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"19 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol was approved by The Affiliated People's Hospital of Ningbo University medical ethics committee (Approval No: 2504250904702), and informed consent was obtained from all patients prior to their participation in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1157"}}